Clinical Trial Details
| Trial ID: | L1490 |
| Source ID: | NCT00527085 |
| Associated Drug: | Amg 073 |
| Title: | 12-month Study of AMG 073 in Renal Osteodystrophy |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Renal Osteodystrophy |
| Interventions: | DRUG: AMG 073|DRUG: Placebo |
| Outcome Measures: | Primary: To evaluate the effects of AMG 073 compared with placebo on renal osteodystrophy as assessed by bone histomorphometry, entire study | Secondary: To evaluate the effects of AMG 073 compared with placebo on intact parathyroid hormone (iPTH), bone-specific alkaline phosphatase (BALP), serum N-Telopeptide (N-Tx), and calcium x phosphorus product concentrations, entire study|To evaluate the feasibility of measuring physical activity with accelerometry, entire study|To evaluate the safety and tolerability of AMG 073 compared with placebo, entire study |
| Sponsor/Collaborators: | Sponsor: Amgen |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 45 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT |
| Start Date: | 2001-10 |
| Completion Date: | 2003-08 |
| Results First Posted: | |
| Last Update Posted: | 2013-05-08 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT00527085 |
